



## PRESS RELEASE

### PAION TO PRESENT AT THREE UPCOMING CONFERENCES

Aachen (Germany), 08 February 2018 – The specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces its participation in three upcoming conferences and investor events. PAION representatives will be available for one-on-one meetings at these events.

2018 BIO CEO & Investor Conference  
12–13 February 2018  
New York Marriott Marquis  
New York, U.S.

12th ODDO BHF German Conference  
21–22 February 2018  
The Westin Grand Hotel  
Frankfurt am Main, Germany

Bio-Europe Spring  
12–14 March 2018  
Amsterdam RAI Convention Center,  
Amsterdam, The Netherlands

###

#### **About PAION**

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in the final stage of clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its development program in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anesthesia was completed in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam.

PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom).

PAION's vision is to become an acknowledged "PAIONeer" in sedation and anesthesia.

#### **PAION Contact**

Ralf Penner  
Vice President Investor Relations/Public Relations  
PAION AG  
Martinstrasse 10-12  
52062 Aachen – Germany  
Phone: +49 241 4453-152  
E-mail: [r.penner@paion.com](mailto:r.penner@paion.com)  
[www.paion.com](http://www.paion.com)

**Disclaimer:**

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.